Significant Major Bleeding in Hospitalized Patients with COVID-19 Receiving Thromboprophylaxis
Thromb Haemost
.
2021 Dec;121(12):1670-1673.
doi: 10.1055/a-1477-4027.
Epub 2021 Jun 6.
Authors
Vicky Mai
1
2
,
Sabine Mainbourg
3
4
,
Boun Kim Tan
4
,
Jean-Christophe Lega
3
4
5
,
Steeve Provencher
1
2
6
Affiliations
1
Institut universitaire de cardiologie et de pneumologie de Québec Research Center, Université Laval, Quebec City, Canada.
2
Pulmonary Hypertension Research Group, Quebec, Cananda.
3
Laboratoire de Biométrie et Biologie Evolutive, Univ Lyon, UMR 5558, Villeurbanne, France.
4
Department of Internal and Vascular Medicine, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre-Bénite, France.
5
Groupe d'Etude Multidisciplinaire des Maladies Thrombotiques (GEMMAT), Hospices Civils de Lyon, Pierre-Bénite, France.
6
Department of Medicine, Université Laval, Quebec City, Canada.
PMID:
33831962
DOI:
10.1055/a-1477-4027
No abstract available
Publication types
Letter
Comment
MeSH terms
Anticoagulants / adverse effects
COVID-19*
Hemorrhage / chemically induced
Humans
SARS-CoV-2
Venous Thromboembolism* / epidemiology
Venous Thromboembolism* / prevention & control
Substances
Anticoagulants